# Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

> **NCT05531786** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 50 (estimated)

## Conditions studied

- Graft vs Host Disease

## Interventions

- **DRUG:** Pacritinib

## Key facts

- **NCT ID:** NCT05531786
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-06
- **Primary completion:** 2027-07-22
- **Final completion:** 2027-07-22
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05531786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05531786, "Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05531786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*